Novartis warns of U.S. price pressure on Sandoz generics
Reuters: Health News
ZURICH (Reuters) - Novartis warned on Wednesday that price pressure on its generics drugs in the United States has intensified in the second quarter, cutting into its Sandoz division's sales growth in the world's largest healthcare market.
(Reuters) - Swiss biotech NLS Pharma AG said on Wednesday mid-stage trial data showed that its drug to treat attention deficit hyperactivity disorder (ADHD) greatly reduced symptoms in adults, paving the way for a late-stage trial.
No comments:
Post a Comment